Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BMXMF NYSE:LH NASDAQ:NTRA OTCMKTS:RMYHY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMXMFbioMerieux$142.45$136.94$96.54▼$143.47$16.86B0.743 shsN/ALHLabcorp$245.73-1.6%$253.73$205.98▼$265.72$20.91B0.82651,938 shs872,473 shsNTRANatera$149.85-5.3%$160.96$92.14▼$183.00$21.60B1.731.42 million shs1.54 million shsRMYHYRamsay Health Care$6.23$5.66$4.44▼$8.46$5.75B0.18133 shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMXMFbioMerieux0.00%0.00%0.00%+11.07%+38.98%LHLabcorp-1.62%-4.64%-5.79%+11.40%+18.43%NTRANatera-5.27%-5.45%-9.37%-0.21%+33.01%RMYHYRamsay Health Care0.00%+8.54%+10.07%+27.40%-18.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMXMFbioMerieuxN/AN/AN/AN/AN/AN/AN/AN/ALHLabcorp4.738 of 5 stars3.32.02.54.22.52.51.9NTRANatera1.6217 of 5 stars2.51.00.00.03.02.50.6RMYHYRamsay Health CareN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMXMFbioMerieux 3.00BuyN/AN/ALHLabcorp 2.57Moderate Buy$276.3812.47% UpsideNTRANatera 3.00Buy$184.6323.21% UpsideRMYHYRamsay Health Care 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest RMYHY, NTRA, LH, and BMXMF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025LHLabcorpHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/10/2025LHLabcorpHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$260.007/9/2025LHLabcorpEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$260.00 ➝ $285.006/25/2025LHLabcorpBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingCautious ➝ Cautious6/25/2025LHLabcorpBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetEqual Weight ➝ Equal Weight$250.00 ➝ $275.006/11/2025LHLabcorpMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$270.00 ➝ $283.005/15/2025NTRANateraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.005/12/2025LHLabcorpTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$274.00 ➝ $290.005/9/2025NTRANateraUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $218.005/9/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.005/7/2025BMXMFbioMerieuxRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMXMFbioMerieux$4.31B3.91$4.48 per share31.79$38.50 per share3.70LHLabcorp$13.01B1.58$22.04 per share11.15$96.27 per share2.55NTRANatera$1.70B12.06N/AN/A$9.05 per share16.56RMYHYRamsay Health CareN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMXMFbioMerieux$467.68MN/A0.00∞N/AN/AN/AN/A9/4/2025 (Estimated)LHLabcorp$746M$8.6528.4114.011.585.55%15.27%6.97%7/24/2025 (Estimated)NTRANatera-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)RMYHYRamsay Health CareN/AN/A0.0025.96N/AN/AN/AN/A8/28/2025 (Estimated)Latest RMYHY, NTRA, LH, and BMXMF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/24/2025Q2 2025LHLabcorp$4.12N/AN/AN/A$3.49 billionN/A5/8/2025Q1 2025NTRANatera-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million4/29/2025Q1 2025LHLabcorp$3.73$3.84+$0.11$2.52$3.41 billion$3.35 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMXMFbioMerieuxN/AN/AN/AN/AN/ALHLabcorp$2.881.17%N/A33.29%N/ANTRANateraN/AN/AN/AN/AN/ARMYHYRamsay Health Care$0.101.61%N/AN/AN/ALatest RMYHY, NTRA, LH, and BMXMF DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/10/2025LHLabcorpquarterly$0.721.11%8/28/20259/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMXMFbioMerieux0.082.201.29LHLabcorp0.681.841.60NTRANateraN/A3.873.74RMYHYRamsay Health CareN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMXMFbioMerieuxN/ALHLabcorp95.94%NTRANatera99.90%RMYHYRamsay Health CareN/AInsider OwnershipCompanyInsider OwnershipBMXMFbioMerieuxN/ALHLabcorp0.84%NTRANatera7.60%RMYHYRamsay Health CareN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMXMFbioMerieux14,600118.36 millionN/ANot OptionableLHLabcorp70,00083.70 million83.00 millionOptionableNTRANatera4,434136.55 million126.17 millionOptionableRMYHYRamsay Health Care88,000923.32 millionN/ANot OptionableRMYHY, NTRA, LH, and BMXMF HeadlinesRecent News About These CompaniesRamsay Health Care (OTCMKTS:RMYHY) Shares Gap Up - Still a Buy?July 10, 2025 | marketbeat.comRamsay Health Care (OTCMKTS:RMYHY) Trading Up 1.4% - What's Next?June 24, 2025 | marketbeat.comRamsay Health Care Limited goes ex dividend MondayMarch 7, 2025 | seekingalpha.comRAMSAY SANTE :Ramsay Health Care Limited Financial advisor announcement - 27 February 2025February 27, 2025 | globenewswire.comAustralia's Ramsay Health Care mulls potential sale of European armFebruary 27, 2025 | reuters.comRMSYF Ramsay Health Care LimitedOctober 17, 2024 | seekingalpha.com‘It’s woke nonsense’ cry Scotland fans as Tartan Army kids asked whether they are trans in ‘creepy’ SFA surveyOctober 11, 2024 | thescottishsun.co.ukTGordon Ramsay’s Daughter Holly Rocks White Lace-Up Corset While Celebrating EngagementOctober 8, 2024 | yahoo.comGordon Ramsay restaurant coming to downtown NapervilleJanuary 18, 2023 | dailyherald.comDHow to book a stay on Ramsay StreetJuly 5, 2022 | msn.comKKR-Led Group Confirms $14 Billion Ramsay Takeover BidMay 21, 2022 | uk.finance.yahoo.comKKR-Led Group Confirms $14 Billion Ramsay Takeover BidMay 19, 2022 | finance.yahoo.comRamsay Health: KKR’s bid for sickly Aussie hospitals group is too lowApril 20, 2022 | finance.yahoo.comAustralia's Ramsay Health Care receives $14.8 billion offer from KKR-led consortiumApril 19, 2022 | finance.yahoo.comRamsay Health Care ADR (RMYHY)January 13, 2022 | nasdaq.comAustralia's Ramsay Health Care to buy mental healthcare group Elysium for $1 billionDecember 14, 2021 | uk.finance.yahoo.comRamsay Health Care reports first quarter earnings hit from elective surgery restrictions, high costsNovember 24, 2021 | markets.businessinsider.comRamsay Health Care Ltd Pref (RHCPA)October 21, 2021 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendRocket Lab: Latest Catalysts Bolster the Bull CaseBy Ryan Hasson | July 3, 2025View Rocket Lab: Latest Catalysts Bolster the Bull Case3 Blockchain Stocks to Profit in a Decentralized WorldBy Chris Markoch | June 24, 2025View 3 Blockchain Stocks to Profit in a Decentralized WorldForget the Fed: Home Depot Is the Real Gauge of the U.S. ConsumerBy Jeffrey Neal Johnson | June 19, 2025View Forget the Fed: Home Depot Is the Real Gauge of the U.S. ConsumerWhy Microsoft Keeps Showing Up in Congressional PortfoliosBy Chris Markoch | July 10, 2025View Why Microsoft Keeps Showing Up in Congressional PortfoliosRMYHY, NTRA, LH, and BMXMF Company DescriptionsbioMerieux OTCMKTS:BMXMF$142.45 0.00 (0.00%) As of 07/14/2025bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.Labcorp NYSE:LH$245.73 -4.07 (-1.63%) Closing price 07/15/2025 03:59 PM EasternExtended Trading$245.60 -0.13 (-0.05%) As of 07/15/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.Natera NASDAQ:NTRA$149.85 -8.33 (-5.27%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$150.39 +0.54 (+0.36%) As of 07/15/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Ramsay Health Care OTCMKTS:RMYHY$6.23 0.00 (0.00%) As of 07/14/2025Ramsay Health Care Limited owns and operates hospitals. The company offers health care services to public and private patients. It operates facilities in approximately 530 locations in the Asia Pacific, the United Kingdom, France, and Nordics. Ramsay Health Care Limited was founded in 1964 and is based in Sydney, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
